【摘要】 目的探讨齐拉西酮的血药浓度测定方法及其临床应用。方法选取2011年10月~2013年7月期间内蒙古精神卫生中心住院的30例蒙古族分裂症患者为研究对象。采用高效液相色谱法分别于齐拉西酮治疗第1、2、4周末测定患者体内齐拉西酮浓度,同时采用阳性与阴性症状量表(PANSS)和治疗时出现的不良反应量表(TESS)来评估临床疗效和不良反应。结果齐拉西酮血药浓度在40~640 ng/m L范围内与峰面积呈现良好的线性关系(r=0.99),最低定量浓度为18 ng/m L,日内日间误差均小于10%。第4周周末所测齐拉西酮浓度与相应的PANSS减分率、日平均剂量呈显著正相关(r>0.4,P<0.05)。结论所使用的高效液相色谱法具有简单、稳定和准确的特点,而且患者体内齐拉西酮浓度具有良好的量效关系,能够指导个体化合理治疗。更多还原

【Abstract】 Objective To investigate determination method of Ziprasidone plasma concentration and its clinical application. Methods 30 cases of Mongolian patients with schizophrenia hospitalized in Mental Health Center of Inner Mongolia Autonomous Region from October 2011 to July 2013 were selected,Ziprasidone plasma concentration in patients was determined by HPLC at first,second,fourth weekend after Ziprasidone treatment respectively. Meanwhile,clinical efficacy and side effects were evaluated by positive and negative syndrome scale(PANSS) and treatment emergent symptom scale(TESS). Results A good linearity was obtained from 40 to 640 ng/m L plasma concentration with peak area(r = 0.99). The quantitation limit was 18 ng/m L,with errors less than 10% for both intra-day and inter-day determinations. The Ziprasidone plasma concentration determined at fourth week had significant positive correlation with PANSS reductive ratio and daily dose(r > 0.4,P < 0.05). Conclusion The used HPLC method has the characteristics of simple,stable and accurate,and Ziprasidone plasma concentration in patients has good concentration-response relationship,which can guide individualized treatment.更多还原